2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo M, Dicko A, Tinto H, Ouédraogo J, Hamaluba M, Olotu A, Beaumont E, Lopez F, Natama H, Weston S, Chemba M, Compaore Y, Issiaka D, Salou D, Some A, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood B, Ewer K, Bradley J, Kulkarni P, Shaligram U, Hill A, Group R, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko O, Kaya M, Maguiraga S, Sankare Y, Yalcouye H, Diarra S, Niambele S, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga R, Samtouma W, Sienou A, Kabre Z, Ouedraogo W, Yarbanga G, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni F, Sanre T, Ouattara S, Provstgaard-Morys S, Woods D, Snow R, Amek N, Ngetsa C, Ochola-Oyier L, Musyoki J, Munene M, Mumba N, Adetifa U, Muiruri C, Mwawaka J, Mwaganyuma M, Ndichu M, Weya J, Njogu K, Grant J, Webster J, Lakhkar A, Ido N, Traore O, Tahita M, Bonko M, Rouamba T, Ouedraogo D, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 2024, 403: 533-544. PMID: 38310910, DOI: 10.1016/s0140-6736(23)02511-4.Peer-Reviewed Original ResearchConceptsClinical malaria episodesPhase 3 trialMalaria episodesMonths age groupAdverse eventsVaccine efficacyClinical malariaMalaria vaccineDouble-blindMalaria transmissionControl vaccineAsn-Ala-Asn-ProAge groupsStandard sitesMonths of follow-upAfrican childrenPerennial malaria transmissionBurden of malariaSeasonal malaria transmissionMalaria transmission intensityPhase 2b trialInjection site painFrequent adverse eventsCo-primary endpointsVaccine-induced antibodies
2021
Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus
Hema-Ouangraoua S, Tranchot-Diallo J, Zongo I, Kabore N, Nikièma F, Yerbanga R, Tinto H, Chandramohan D, Ouedraogo G, Greenwood B, Ouedraogo J. Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus. PLOS ONE 2021, 16: e0257190. PMID: 34644317, PMCID: PMC8513893, DOI: 10.1371/journal.pone.0257190.Peer-Reviewed Original ResearchConceptsAdministration of azithromycinSerious illnessS. aureusEffectiveness of azithromycinMalaria transmission seasonVulnerable pediatric populationS. aureus isolatesImpact of azithromycinNasal carriageRespiratory infectionsSulfadoxine-pyrimethaminePediatric populationClinical trialsAzithromycin resistanceNasal swabsAureus isolatesTransmission seasonAzithromycinPrevalent strainsMajor causeAdministrationPlaceboStaphylococcus aureusChildrenIllnessCharacteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials
Wessells K, Arnold C, Stewart C, Prado E, Abbeddou S, Adu-Afarwuah S, Arnold B, Ashorn P, Ashorn U, Becquey E, Brown K, Byrd K, Campbell R, Christian P, Fernald L, Fan Y, Galasso E, Hess S, Huybregts L, Jorgensen J, Kiprotich M, Kortekangas E, Lartey A, Le Port A, Leroy J, Lin A, Maleta K, Matias S, Mbuya M, Mridha M, Mutasa K, Naser A, Paul R, Okronipa H, Ouédraogo J, Pickering A, Rahman M, Schulze K, Smith L, Weber A, Zongrone A, Dewey K. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. American Journal Of Clinical Nutrition 2021, 114: 68-94. PMID: 34590114, PMCID: PMC8560313, DOI: 10.1093/ajcn/nqab276.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsPrevalence of anemiaIndividual participant dataIron deficiencyRetinol-binding proteinEffect modifiersChild anemiaSmall-quantity lipid-based nutrient supplementationStatus outcomesIndividual-level effect modifiersLipid-based nutrient supplementationLipid-based nutrient supplementsParticipant dataIndividual-level modifiersIron deficiency anemiaFe/dMo of ageFixed-effects modelDeficiency anemiaChild's hemoglobinEffect modificationIron statusChildren 6Study design characteristicsPlasma zincEffectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite densitySeasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R, Diarra M, Nikièma F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou A, Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouédraogo J, Dicko A, Greenwood B. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2021, 385: 1005-1017. PMID: 34432975, DOI: 10.1056/nejmoa2026330.Peer-Reviewed Original ResearchConceptsUncomplicated malariaProtective efficacyClinical malariaSevere malariaMalaria-related outcomesSeasonal malaria chemopreventionUncomplicated clinical malariaVaccine-alone groupWorld Health Organization definitionPrespecified noninferiority marginMonths of ageMalaria chemopreventionSeasonal vaccinationFirst doseHazard ratioMalaria vaccinationFebrile seizuresHospital admissionCombination groupNoninferiority marginLower incidenceAS01ChemopreventionChildren 5Organization definitionNutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria
de Wit M, Cairns M, Compaoré Y, Sagara I, Kuepfer I, Zongo I, Barry A, Diarra M, Tapily A, Coumare S, Thera I, Nikiema F, Yerbanga R, Guissou R, Tinto H, Dicko A, Chandramohan D, Greenwood B, Ouedraogo J. Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria. Malaria Journal 2021, 20: 274. PMID: 34158054, PMCID: PMC8220741, DOI: 10.1186/s12936-021-03802-2.Peer-Reviewed Original ResearchConceptsClinical malaria incidenceSeasonal malaria chemopreventionMalaria transmission seasonClinical malariaNutritional statusMalaria incidenceMalaria chemopreventionSubsequent incidenceTransmission seasonMalaria seasonNutritional indicatorsEffects of malnutritionYoung childrenSymptomatic malariaScreening visitArm circumferenceLower incidenceModerate wastingHigh incidenceRandom effects Poisson modelBurkina FasoInsecticidal netsMalaria controlMalnutritionMalariaHepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2020
Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali
Cairns M, Sagara I, Zongo I, Kuepfer I, Thera I, Nikiema F, Diarra M, Yerbanga S, Barry A, Tapily A, Coumare S, Milligan P, Tinto H, Ouédraogo J, Chandramohan D, Greenwood B, Djimde A, Dicko A. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLOS Medicine 2020, 17: e1003214. PMID: 32822362, PMCID: PMC7442230, DOI: 10.1371/journal.pmed.1003214.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionUncomplicated malariaTransmission seasonIntense seasonal malaria transmissionDay 28 PCRParasitological response rateUncomplicated clinical malariaPlacebo-controlled trialIncidence of hospitalisationSeasonal malaria transmissionIncidence rate ratiosBurden of malariaRapid diagnostic testsBougouni DistrictAsymptomatic malariaClinical malariaPlacebo groupStudy drugMalaria parasitaemiaAge range 3Parent trialAmodiaquine resistancePrevalence ratiosProtective efficacyInvestigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso
Somé FA, Bazié T, Ehrlich HY, Goodwin J, Lehane A, Neya C, Zachari K, Wade M, Ouattara JM, Foy BD, Dabiré RK, Parikh S, Ouédraogo JB. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malaria Journal 2020, 19: 238. PMID: 32631416, PMCID: PMC7339464, DOI: 10.1186/s12936-020-03311-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDay 7 concentrationsSMC administrationMalaria chemopreventionMalaria infectionDay 7 plasma concentrationsHigh malaria transmission seasonBlood spotsFirst monthPfcrt 76TPrevalence of microscopicSubmicroscopic malaria infectionMalaria transmission seasonPlasmodium falciparum infectionPfcrt K76THigh transmission settingsSequential cross-sectional surveysCross-sectional surveyNon-significant trendAmodiaquine metabolismPfmdr1 N86Malaria parasitaemiaFalciparum infectionK76TPlasma concentrationsDifferent distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission
Pigeault R, Isaïa J, Yerbanga R, Dabiré K, Ouédraogo J, Cohuet A, Lefèvre T, Christe P. Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission. Scientific Reports 2020, 10: 10183. PMID: 32576924, PMCID: PMC7311528, DOI: 10.1038/s41598-020-67180-6.Peer-Reviewed Original ResearchConceptsGametocyte densityMosquito infection ratesBlood samplesInfection rateNew malaria control strategiesMajor global causeMalaria control strategiesLow parasite burdenGametocyte burdenGametocyte carriersParasite transmissionPlasmodium infectionMosquito transmission potentialRight extremitiesTransmissible stagesParasite burdenMosquito transmissionMalaria parasitesPlasmodium sppGlobal causeTransmission potentialGametocytesVector-borne diseasesDiseaseExtremitiesSerotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin
Hema-Ouangraoua S, Zongo I, Kabore N, Frédéric N, Yerbanga R, Tinto H, Compaore Y, Kuepfer I, Chandramohan D, Greenwood B, Ouedraogo J. Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin. American Journal Of Tropical Medicine And Hygiene 2020, 103: 679-683. PMID: 32524945, PMCID: PMC7410481, DOI: 10.4269/ajtmh.19-0944.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoCarrier StateChemopreventionChild, PreschoolDrug CombinationsDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansInfantMalariaMaleMass Drug AdministrationNasopharynxPneumococcal InfectionsPneumococcal VaccinesPyrimethamineSeasonsSerogroupStreptococcus pneumoniaeSulfadoxineConceptsSeasonal malaria chemopreventionMass drug administrationEmergence of resistancePneumococcal serotypesDrug AdministrationStreptococcus pneumoniaeDistribution of serotypesMalaria chemopreventionNasopharyngeal isolatesMass administrationCarriage studiesAzithromycinQuellung techniqueSwift appearanceSpecific serotypesSingle serotypeAdministrationAntibiotic resistanceSerotype profileSerotypesDifferent serotypesMultiplex assayPneumoniaePCR techniqueIsolatesEffect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children
Gore‐Langton G, Cairns M, Compaoré Y, Sagara I, Kuepfer I, Zongo I, de Wit M, Barry A, Diarra M, Tapily A, Coumare S, Thera I, Nikiema F, Yerbanga R, Guissou R, Tinto H, Dicko A, Chandramohan D, Greenwood B, Ouedraogo J. Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children. Tropical Medicine And International Health 2020, 25: 740-750. PMID: 32166877, DOI: 10.1111/tmi.13390.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria transmission seasonMalaria chemopreventionNutritional statusTransmission seasonTreatment armsAddition of azithromycinEffect of azithromycinNutritional status indicatorsCross-sectional surveyHospital admissionRecent trialsMass administrationAnthropometric measurementsChronic malnutritionAzithromycinAfrican childrenChemopreventionNutritional outcomesBurkina FasoContinuous outcomesStudy periodMode of actionProtocol analysisYoung childrenEfficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDaysThe duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalenceIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2019
Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae
Hema‐Ouangraoua S, Maiga A, Cairns M, Zongo I, Frédéric N, Yerbanga R, Tamboura B, Badji H, Gore‐Langton G, Kuepfer I, Tinto H, Sagara I, Dicko A, Sow S, Chandrahoman D, Greenwood B, Ouedraogo J. Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae. Tropical Medicine And International Health 2019, 24: 1442-1454. PMID: 31655020, PMCID: PMC7687265, DOI: 10.1111/tmi.13321.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria chemopreventionNasopharyngeal swabsStreptococcus pneumoniaeAnnual malaria transmission seasonsMalaria transmission seasonResistance of pneumococciMalian childrenHospital admissionAzithromycin 1Nasal isolatesAntimalarial combinationLast administrationPneumococcal isolatesTransmission seasonDrug AdministrationAzithromycinChemopreventionResistant isolatesAntimalarialsAntimicrobial resistancePlaceboBurkina FasoChildrenEffect of Adding Azithromycin to Seasonal Malaria Chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Barry A, Tapily A, Nikiema F, Yerbanga S, Coumare S, Thera I, Traore A, Milligan P, Tinto H, Doumbo O, Ouedraogo J, Greenwood B. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2019, 380: 2197-2206. PMID: 30699301, DOI: 10.1056/nejmoa1811400.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoChild MortalityChild, PreschoolDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansIncidenceInfantInfant MortalityMalariaMaleMaliMass Drug AdministrationParasitemiaPyrimethamineSulfadoxineConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria transmission seasonMalaria chemopreventionHospital admissionAnnual malaria transmission seasonsUpper respiratory tract infectionNonmalarial febrile illnessesPrimary end pointRespiratory tract infectionsAntimalarial agentsLow disease burdenYears of ageMonths of ageAzithromycin groupCause mortalityPlacebo groupAdverse eventsFebrile illnessMalaria parasitemiaTract infectionsTreat analysisElective surgeryDisease burdenGastrointestinal infectionsOptimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children
Chotsiri P, Zongo I, Milligan P, Compaore Y, Somé A, Chandramohan D, Hanpithakpong W, Nosten F, Greenwood B, Rosenthal P, White N, Ouédraogo J, Tarning J. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nature Communications 2019, 10: 480. PMID: 30696903, PMCID: PMC6351525, DOI: 10.1038/s41467-019-08297-9.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionSmall childrenPlasmodium falciparum malariaHigh transmission seasonLower drug exposureSigmoidal Emax modelHigh transmission periodYoung childrenAlternative regimenFalciparum malariaDose scheduleMonthly dosesOptimal dosingDrug exposurePreventive efficacyTransmission seasonPharmacokinetic parametersBody weightEmax modelMalaria incidenceVulnerable populationsHigh dosageChildrenChemopreventionEvaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, Soulama I, Ouedraogo J, Beavogui A, Borghini-Fuhrer I, Khan Y, Djimdé A, Voiriot P. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports 2019, 9: 883. PMID: 30696921, PMCID: PMC6351684, DOI: 10.1038/s41598-018-37113-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyQTc prolongationHeart rate changesCombination therapyVentricular repolarizationQT/QTc interval prolongationEvidence of proarrhythmiaQTc interval prolongationQTc assessmentLethal ventricular arrhythmiasExtent of prolongationMalaria crisisArtemether-lumefantrineInterval prolongationVentricular arrhythmiasAfrican patientsClinical safetyFirst episodeQT intervalHeart rateAntimalarial drugsProlongationQT correctionECG recordingsHigh-quality ECG recording
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infection